Original news and analysis on international IP policy
The Medicines Patent Pool announced today that it has signed a license agreement with Johns Hopkins University for a candidate tuberculosis treatment. Although seen as a major step forward by public health groups, they said the agreement does not include guarantees that the treatment that could be brought to the market would be affordable for all.
At the opening of the World Health Organization Executive Board meeting today, a call by India for an agenda item on the report of the United Nations Secretary-General’s High-Level Panel on Access to Medicines was denied. Meanwhile, WHO’s director general underlined the success of the organisation over the last year, including new financing arrangements with industry groups to finance the WHO Prequalification Programme. But all eyes are riveted to the election process for the new WHO director general, as three out of the six candidates are expected to be short-listed this week.
Although the main governing body of the World Health Organization is the annual World Health Assembly held in May, many decisions are made at the annual January session of the WHO Executive Board. Among the topics to be discussed next week are the election of a new director general, antimicrobial resistance, the financing of research and development for health products.
The World Health Organization recently published its analysis about the public health implications of the Nagoya Protocol on genetic resources access and benefit-sharing, and in particular how it affects the sharing of pathogens, like influenza viruses. The findings are set to be discussed at this month’s WHO Executive Board meeting. Also to be discussed is an experts group review of the WHO pandemic influenza framework, and in particular its conclusion that the framework should be amended to match scientific progress.
The World Intellectual Property Organization internet platform WIPO GREEN is expanding by building a database of experts meant to help technology seekers find green technology specialists to provide their service and expertise.
Days away from the opening of the annual World Economic Forum in Davos, the founder of the forum described the main themes of the upcoming event, and underlined the role of social responsibility for business leaders.
Climate change is prompting the need for new technologies to address the consequences of the weather changing patterns. A book authored by a number of scholars provides an introduction to the interactions of climate change with the global intellectual property, innovation, human rights and international trade systems.
The book Antitrust Issues in Intellectual Property Law, edited by Bradford Lyerla and authored by several lawyers, is about the intersection of IP law and antitrust law and collects case law from 2015 and 20152016??, dealing with the issue.
Biotherapeutic medicines are made out of living organisms and cannot be replicated. No generic medicines, which are exact copies of the reference product, can be made. The generic equivalent of a biotherapeutic would be biosimilars, which are highly similar products. The United States Food and Drug Administration has issued a guide to help producers to prove how close their biosimilars are to the biotherapeutics.
As a new year dawns, a lot of movement has been observed in the pharmaceutical industry with new key players taking the lead. Meanwhile, new delegates are covering IP issues in Geneva, and coordination of regional groups at the World Intellectual Property Organization makes its usual yearly shift for 2017. The copyright industry also saw major changes, and law offices have been busy hiring new partners.
The Executive Board of UNITAID yesterday adopted a resolution on the use of the intellectual property flexibilities enshrined in the global trading system allowing developing countries to facilitate access to affordable medicines.
After a day spent in informal meetings to try to agree on what should be the future work of the World Intellectual Property Organization patent law committee, delegates had to admit defeat. The main point of contention, according to sources, was the request by developing countries that the committee work on the issue of patents and access to medicines, and address the recommendations of the United Nations Secretary-General’s High Level Panel on Access to Medicines. This request was met by blunt refusal by some developed countries as beyond the realm of the work of the committee.